Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio

Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices 

Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global Jurisdictions Acknowledge the Uniqueness of the LIBERTY System

Read more at globenewswire.com